Aegerion Pharmaceuticals, Inc. (AEGR) Message Board
- Reply to
The ISIS drug DOESN'T WORK, other than that, it's great
by yassen_gregorivich •May 20, 2013 1:44 PMThat is why they YELL about the ISIS drug, because anybody who does any research sees the efficacy at less than half of AEGRs drug.
- Reply to
Short 13000 shares this afternoon between 41.50-41.90
by adamwangwang47 •Apr 30, 2013 9:25 PMI believe you. It IS killing you. Time to dump that alias and get another one. Oh wait, you already did that.
- Reply to
I shorted at $63 yesterday but covered too soon today at $60.50. What a shame!
by holywallst •May 17, 2013 12:24 PMSure you did.
What happened to your short at $40? -
Looks like you were right.
- Reply to
AEGR approval by the EU next month (5/25/2013)
by system_architect_enterprise •Apr 26, 2013 1:31 PM5/25/2013 is the meeting start date. Yahoo filters garbled the date.
-
So what is the next call? Last chance to get in under $60 or is that already gone?
-
So Adam, I see you have another alias. How is that $15 short treating you?
The way you shorted more at $25 and $30; truly nimble.
Then to announce your shorting even more at $40, $41, and $44, absolutely God-Like.
The God of losing money. -
He may be losing his mind, but you are losing your #$%$
- Reply to
AEGR approval by the EU next month (5/25/2013)
by system_architect_enterprise •Apr 26, 2013 1:31 PMEU CHMP approval coming in a few weeks ...
-
Changing directors on the board won't help it. It is too late for that. Too many things have gone wrong already. New management is needed. Swap out the entire executive management team. The sales are so atrocious it is a joke. They should have already resigned, except they can't get a job anywhere else. So they will have to be fired. We can do it sooner or later, but it will happen eventually.
-
The more it trends up, the more pressure on the shorts to cover. Pushing the rally higher.
-
What do your Rice Seeds say about Benghazi and the IRS?
-
Shorts like Adam continue to get killed. Bragging about how smart they were to short at $15, how they doubled their short position at $25, increased it at $30, and $35, then even more at $40 and $42. They keep pushing a bad position. If we do hit the $100/share target is year, I wonder if they will keep shorting every step of the way. It just increases the amount they will have to cover, creating more pent up demand.
- Reply to
AEGR approval by the EU next month (5/25/2013)
by system_architect_enterprise •Apr 26, 2013 1:31 PMSo the EU approval will effectively triple the market that they are going after.
- Reply to
Pretty Obvious At This Point FDA to Grant AA , As Soon As Gets Paperwork.
by supermanjoe •May 9, 2013 10:33 AMAgreed. The FDA appears to be trying to help patients by working with SRPT to get AA as quickly as possible while still ensuring defendable legal rigor.
- Reply to
CEO " We Believe The FDA Will Partner With Us To Get The Product To Patients Needing It" LINK
by tommyhill685 •May 9, 2013 10:12 AMDo not confuse "partner" meaning - when a group works diligently towards the same goal as another group - with a formal/legal partnership. They were referring to working together towards a common goal.
- Reply to
IGXT (Mcap $31 M) 4x FDA approvals within 1 Year & Profitable this Year = 10++ Bagger Potential !!!
by medicalstarb •May 8, 2013 9:26 AMWow. It must be a truly horrible stock if its shareholders have to spam other message boards begging and pleading for people to buy it.
-
Interestingly enough, there is another hatchet job against AEGR by Forbes. Remember that Forbes was the one who tried to skew the facts on the AMGN drug compared with the AEGR drug. Now Forbes has yet another article that is artificially against AEGR.
-
Latin ...
Do what you are doing.
Experience is the teacher of fools. (You have to learn by making mistakes).
Rest in Peace. (or "It's your funeral"). -
It will take time to realize that potential value. Nobody ever has 100% marketshare, so what we need to assess is what the achievable marketshare is in order to determine the valuation. Certainly 10% market penetration is very easy to do and not over the top, so the $120-$240/share valuation is definitely in play. Who knows what the total global market is that is achievable, because there is no way that all 10,000 patients will be able to get the medication at these prices. Sure maybe the EU will kick in for a lot of them, given the socialist nature of their medicine, but the US even with Obamacare won't pick up that big a tab for those without insurance. So does that mean the total market is 3/4? 1/2? Only time will tell.